The report provides an overview of the potential of CRISPR-based therapeutics in the infectious disease space.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a precision gene-editing tool that enables targeted modification of DNA. It uses a guide RNA to direct a Cas enzyme (such as Cas9 or Cas12) to a specific genetic sequence, where it creates a cut and allows for the insertion, deletion, or correction of DNA. In infectious diseases, CRISPR may be used to directly disrupt viral genomes, edit host susceptibility genes, or engineer immune cells to fight persistent pathogens.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a precision gene-editing tool that enables targeted modification of DNA. It uses a guide RNA to direct a Cas enzyme (such as Cas9 or Cas12) to a specific genetic sequence, where it creates a cut and allows for the insertion, deletion, or correction of DNA. In infectious diseases, CRISPR may be used to directly disrupt viral genomes, edit host susceptibility genes, or engineer immune cells to fight persistent pathogens.
Key Highlights
- Report deliverables in the form of a Pdf report
- Global scope of pipeline products
Scope
- Overview of CRISPR gene editing, including history of development
- Assessment of unmet needs and challenges in the space (gap anlysis)
- Profiles of key pipeline products and emerging companies
- Overview of major deals and acquisitions in the space between 2013 and 2025
- Insights into ethical considerations and future outlook
Reasons to Buy
- Develop an understanding of the potential of CRISPR-based therapeutics in the infectious disease space.
- Gain insights into the innovative products and technologies, and emerging companies with potential to shape the future market.
- Recognize gaps, challenges, and areas of unmet need within this space.
- Identify opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1. Executive summary2. CRISPR Gene Editing Overview
3. Unmet Needs and Challenges
4. Pipeline Products
5. Clinical Trials
6. Companies
7. Deals
8. Ethics
9. Regulation
10. Opportunities and Future Outlook
11. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Excision BioTherapeutics
- Locus Biosciences
- Intellia Therapeutics
- Shanghai BDgene Therapeutics Co
- SNIPR Biome
